AstraZeneca - Big Pharma's Q2 2010 Earnings Report

FiercePharma says: AstraZeneca reported stronger-than-expected second-quarter earnings. It hiked its 2010 forecast for the third time, and announced a $2 billion share-buyback program. Crestor steamed forward with a 23 percent increase in second-quarter sales, fueling the company's 23 percent rise in Q2 profits, to $2.11 billion.

Highlights

  • Revenue for the second quarter increased by 1 percent at constant exchange rates (CER) to $8,178 million.
  • Core operating profit in the second quarter was $3,650 million, unchanged at CER, as lower other operating income offset increased revenue and lower operating costs.
  • Core EPS in the second quarter increased by 9 percent at CER to $1.79.
  • Reported EPS in the second quarter increased by 22 percent at CER to $1.46.
  • Crestor patent upheld by US Court in a ruling announced on 29 June 2010.
  • The Board has recommended a first interim dividend of $0.70. Target for net share repurchases is increased to $2 billion for 2010.
  • Core EPS target for the full year increased to the range of $6.35 to $6.65.

See AstraZeneca's current stock quote from CNN Money

AstraZeneca's website: http://www.astrazeneca.com/
Full earnings release: AstraZeneca release

AstraZeneca - Big Pharma's Q2 2010 Earnings Report
Read more on

Suggested Articles

The second of AbbVie’s highly anticipated 2019 blockbuster candidates is here: Its crucial Humira follow-up, Rinvoq.

Bristol-Myers Squibb’s takeover of Celgene hasn’t always gone smoothly, but now a once-left-for-dead centerpiece of that deal is ready to launch.

Investors sued Novo Nordisk in Denmark, claiming it misled the public about trouble plaguing its insulin franchise—and demanding $1.75B in damages.